Drugs / Convalesscent Plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04433910 | Aug 2020 → Jan 2021 | COVID-19 | German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Convalesscent Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04433910 ↗ |
| Known as | CCP | “COVID-19 convalescent plasma (CCP) has been considered a treatment option for COVID-19.” PMID 34464358 ↗ Oct 2021 |
| Route | Other | “Convalescent plasma transfusion on day 1, 3 and 5.” NCT04433910 ↗ |